COSCIENS Biopharma Inc. Completes Share Capital Amendment
COSCIENS Biopharma Inc. (TSX: CSCI; OTCQB: CSCIF) said its share capital amendment took effect July 3, 2026: a 1-for-150 share consolidation followed by a 50-for-1 split. Holders with <150 shares received US$1.60 per share; others received replacement shares. Trading on a post-amendment basis is expected on the TSX within two business days; the company plans a July 6 Form 15 to suspend U.S. reporting.
How this was made
The 30-second read
Why it matters
The effective-date corporate action changes the share count and entitlements, and the planned Form 15 filing suggests an upcoming reduction in US reporting obligations, which can affect investor base and liquidity.
Market read
Traders may need to adjust positions for the new share structure and anticipate short-term liquidity/price-per-share distortions around the TSX post-amendment trading start.
What to watch
Watch for settlement/DRS processing frictions and the cash payment mechanics for holders under 150 shares, which can temporarily distort order books and spreads.
Background
COSCIENS announced a share capital amendment combining a 1-for-150 consolidation with an immediate 50-for-1 split, plus cash consideration for small holders.
Ticker impact
The company also notes the share capital amendment became effective today and expects TSX trading to resume post-amendment; OTCQB symbol is referenced as CSCIF.
Modest, short-lived dislocations in OTC pricing/liquidity are possible; sustained repricing is unlikely without new fundamentals.
The article explicitly details TSX trading resumption timing, while OTC implications are not spelled out; CSCIF is mentioned as the OTC symbol, so the OTC impact is inferred rather than directly stated.
Market effects
Limited read-across; this is a microcap corporate-action and SEC reporting-change mechanics update rather than a sector catalyst.
Potential localized volatility in Canadian microcap trading/settlement around the TSX post-amendment start.
Low; the SEC Form 15 intent may reduce US reporting burden but does not indicate a fundamental business change.
Counterpoint
Because the consolidation/split is largely mechanical, any price move may fade quickly once the market adjusts to the new share count and cash-out mechanics.
Key entities
- issuerCOSCIENS Biopharma Inc.
Announced the effective date of its share capital amendment (consolidation + split) and cash payment for holders under 150 shares.
- agentComputershare Investor Services Inc.
Named as depositary/exchange agent for letters of transmittal and DRS certificate/advices surrender.
- regulatorU.S. Securities and Exchange Commission (SEC)
Company expects to file a Form 15 on July 6, 2026 to suspend US reporting obligations.
